Fig. 2.

Evaluation of the composite cytokine signature in the training dataset (CheckMate 009 and 025) and validation of the signature in the test dataset (CheckMate 010) by comparing the outcome association from a actual nivolumab clearance in the training dataset; b predicted clearance using the composite cytokine signature in the training dataset; c actual nivolumab clearance in the test dataset; and d predicted clearance using the composite cytokine signature in the test dataset. High CL patients with high actual clearance, low CL patients with low actual clearance, OS overall survival, predicted high CL patients predicted to have high clearance from the cytokine signature, predicted low CL patients predicted to have low clearance from the cytokine signature